Surgical Science Sweden AB (publ) (SUS) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Surgical Science Q2 Report 2026 presentation. During the Q&A session, participants can ask questions by pressing pound key 5 on their telephone keypad. During the Q&A, we kindly ask participants to limit yourselves to two questions at first. If you have additional questions, please queue up again by pressing pound key 5. Now, I will hand over to the speakers, CEO Tom Englund and CFO Anna Ahlberg. Please go ahead. Hi everyone and welcome to this earnings call for Certical Science for the second quarter of 2026. My name is Tom Englund, I'm the CEO and with me today is our CFO Anna Ahlberg. We'll start with a walkthrough of quarter two and the numbers and then we'll open up for questions. Quarter two was a strong quarter and I want to say that clearly upfront. We exceeded our financial targets on growth. Profitability was in line with our financial target and license revenues were strong. Revenue came in at 255 million SEK, up 22% reported and 25% in local currencies. Just a little bit reached 38 million SEC with a margin of 15%, which is a significant recovery from quarter two last year, which was an unusually weak comparison quarter. And it's a clear sign that the actions that we've taken to improve profitability and our customer offering are working. The gross margin improved to 69% up from 65% in the same period last year. This reflects both the stronger mix of license revenues and the profitability improvements that we've seen and have been driving in the simulator business. And gross margin excluding licenses also improved several percentage points. And I'll come back to what's behind that later. Licensed revenues for the quarter were 85 million SEK, up 44% year-over-year, and that's a strong number and reflects the momentum in the robotics market and t...